These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 36636808)

  • 1. Efficacy of sofpironium bromide gel on clozapine-induced hypersalivation in patients with treatment-resistant schizophrenia: double-blind, controlled crossover study.
    Amano Y; Mazda J; Amano K; Ohi K; Shioiri T
    BJPsych Open; 2023 Jan; 9(1):e14. PubMed ID: 36636808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glycopyrrolate in comparison to hyoscine hydrobromide and placebo in the treatment of hypersalivation induced by clozapine (GOTHIC1): study protocol for a randomised controlled feasibility study.
    Qurashi I; Chu S; Husain N; Drake RJ; Chaudhry I; Deakin JF
    Trials; 2016 Nov; 17(1):553. PubMed ID: 27871302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Scopolamine Butylbromide on Clozapine-induced Hypersalivation in Schizophrenic Patients: A Case Series.
    Takeuchi I; Suzuki T; Kishi T; Kanamori D; Hanya M; Uno J; Fujita K; Kamei H
    Clin Psychopharmacol Neurosci; 2015 Apr; 13(1):109-12. PubMed ID: 25912544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Double-Blind, Randomized, Placebo-Controlled Trial of Metoclopramide for Hypersalivation Associated With Clozapine.
    Kreinin A; Miodownik C; Mirkin V; Gaiduk Y; Yankovsky Y; Bersudsky Y; Lerner PP; Bergman J; Lerner V
    J Clin Psychopharmacol; 2016 Jun; 36(3):200-5. PubMed ID: 27028980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of sublingual atropine sulfate on clozapine-induced hypersalivation: a multicentre, randomised placebo-controlled trial.
    Mubaslat O; Lambert T
    Psychopharmacology (Berl); 2020 Oct; 237(10):2905-2915. PubMed ID: 32876732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyoscine for clozapine-induced hypersalivation: a double-blind, randomized, placebo-controlled cross-over trial.
    Segev A; Evans A; Hodsoll J; Whiskey E; Sheriff RS; Shergill S; MacCabe JH
    Int Clin Psychopharmacol; 2019 Mar; 34(2):101-107. PubMed ID: 30614850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment effects of traditional Chinese medicines Suoquan Pill and Wuling Powder on clozapine-induced hypersalivation in patients with schizophrenia: study protocol of a randomized, placebo-controlled trial.
    Hung CC; Fu PK; Wang HY; Chan CH; Lan TH
    Zhong Xi Yi Jie He Xue Bao; 2011 May; 9(5):495-502. PubMed ID: 21565135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anticholinergic medication for non-clozapine neuroleptic-induced hypersalivation in people with schizophrenia.
    Essali A; Rihawi A; Altujjar M; Alhafez B; Tarboush A; Alhaj Hasan N
    Cochrane Database Syst Rev; 2013 Dec; 2013(12):CD009546. PubMed ID: 24353163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two-week prospective observational study of 5% sofpironium bromide gel in Japanese patients with primary axillary hyperhidrosis.
    Fujimoto T; Okatsu H; Miyama H
    J Dermatol; 2022 Jun; 49(6):594-599. PubMed ID: 35394087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase 3, multicenter, randomized, double-blind, vehicle-controlled, parallel-group study of 5% sofpironium bromide (BBI-4000) gel in Japanese patients with primary axillary hyperhidrosis.
    Yokozeki H; Fujimoto T; Abe Y; Igarashi M; Ishikoh A; Omi T; Kanda H; Kitahara H; Kinoshita M; Nakasu I; Hattori N; Horiuchi Y; Maruyama R; Mizutani H; Murakami Y; Watanabe C; Kume A; Hanafusa T; Hamaguchi M; Yoshioka A; Egami Y; Matsuo K; Matsuda T; Akamatsu M; Yorozuya T; Takayama S
    J Dermatol; 2021 Mar; 48(3):279-288. PubMed ID: 33410265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase III, 52-week, open-label study to evaluate the safety and efficacy of 5% sofpironium bromide (BBI-4000) gel in Japanese patients with primary axillary hyperhidrosis.
    Fujimoto T; Abe Y; Igarashi M; Ishikoh A; Omi T; Kanda H; Kitahara H; Kinoshita M; Nakasu I; Hattori N; Horiuchi Y; Maruyama R; Mizutani H; Murakami Y; Watanabe C; Kume A; Hanafusa T; Hamaguchi M; Yoshioka A; Egami Y; Matsuo K; Matsuda T; Akamatsu M; Yorozuya T; Takayama S; Yokozeki H
    J Dermatol; 2021 Aug; 48(8):1149-1161. PubMed ID: 34041788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic effect of pirenzepine for clozapine-induced hypersalivation: a randomized, double-blind, placebo-controlled, cross-over study.
    Bai YM; Lin CC; Chen JY; Liu WC
    J Clin Psychopharmacol; 2001 Dec; 21(6):608-11. PubMed ID: 11763010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of the repeated administration of scopolamine ointment on clozapine-induced hypersalivation in patients with treatment-resistant schizophrenia: A preliminary study.
    Takeuchi I; Hanya M; Uno J; Fujita K; Kamei H
    Asia Pac Psychiatry; 2017 Dec; 9(4):. PubMed ID: 29193710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clozapine-induced hypersalivation: an estimate of prevalence, severity and impact on quality of life.
    Maher S; Cunningham A; O'Callaghan N; Byrne F; Mc Donald C; McInerney S; Hallahan B
    Ther Adv Psychopharmacol; 2016 Jun; 6(3):178-84. PubMed ID: 27354906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of clozapine-induced hypersalivation with ipratropium bromide: a randomized, double-blind, placebo-controlled crossover study.
    Sockalingam S; Shammi C; Remington G
    J Clin Psychiatry; 2009 Aug; 70(8):1114-9. PubMed ID: 19758522
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amisulpride treatment of clozapine-induced hypersalivation in schizophrenia patients: a randomized, double-blind, placebo-controlled cross-over study.
    Kreinin A; Novitski D; Weizman A
    Int Clin Psychopharmacol; 2006 Mar; 21(2):99-103. PubMed ID: 16421461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trihexyphenidyl treatment of clozapine-induced hypersalivation.
    Spivak B; Adlersberg S; Rosen L; Gonen N; Mester R; Weizman A
    Int Clin Psychopharmacol; 1997 Jul; 12(4):213-5. PubMed ID: 9347382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential use of ipatropium bromide for the treatment of clozapine-induced hypersalivation: a preliminary report.
    Calderon J; Rubin E; Sobota WL
    Int Clin Psychopharmacol; 2000 Jan; 15(1):49-52. PubMed ID: 10836287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sofpironium Bromide: First Approval.
    Paik J
    Drugs; 2020 Dec; 80(18):1981-1986. PubMed ID: 33236266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Memantine augmentation in clozapine-refractory schizophrenia: a randomized, double-blind, placebo-controlled crossover study.
    Veerman SR; Schulte PF; Smith JD; de Haan L
    Psychol Med; 2016 Jul; 46(9):1909-21. PubMed ID: 27048954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.